Raptor Pharmaceutical Corp. (RPTP)

[surf1944]

8:37AM Raptor Pharma's PROCYSBI receives positive recommendation from CHMP (RPTP) 9.37 : Co announced that the European Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending marketing authorization for PROCYSBI 25mg and 75mg gastro-resistant hard capsules, cysteamine (as mercaptamine bitartrate) for the treatment of proven nephropathic cystinosis. If approved, PROCYSBI will be indicated for the treatment of proven nephropathic cystinosis. A decision is expected from the European Commission within a few months of the CHMP recommendation.